Molecular Partners AGMolecular Partners AGMolecular Partners AG

Molecular Partners AG

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪151.02 M‬USD
−2.27USD
‪−59.51 M‬USD
‪5.47 M‬USD
‪31.05 M‬
Beta (1Y)
0.89
Employees (FY)
174
Change (1Y)
−8 −4.40%
Revenue / Employee (1Y)
‪31.45 K‬USD
Net income / Employee (1Y)
‪−341.99 K‬USD

About Molecular Partners AG


CEO
Patrick Amstutz
Headquarters
Schlieren
Founded
2004
ISIN
CH0256379097
FIGI
BBG00L53GM78
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Check out other big names from the same industry as MLLCF.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CHSPI
iShares Core SPI(R) ETF (CH)
Weight
0.01%
Market value
‪333.23 K‬
USD
SPICHA
UBS ETF (CHF) - UBS Core SPI(R) ETF Anteile CHF dis
Weight
0.00%
Market value
‪84.84 K‬
USD
SPIA
UBS ETF (CH) - SPI (R) Units -CHF acc-
Weight
0.00%
Market value
‪84.84 K‬
USD
SPISI
UBS ETF (CH) - UBS SPI(R) ESG ETF Units -CHF acc-
Weight
0.00%
Market value
‪60.03 K‬
USD
SPISID
UBS ETF (CH) - SPI (R) ESG Units -CHF dis-
Weight
0.00%
Market value
‪60.03 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of MLLCF is 3.50 USD — it has increased by 1.45% in the past 24 hours. Watch Molecular Partners AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Molecular Partners AG stocks are traded under the ticker MLLCF.
We've gathered analysts' opinions on Molecular Partners AG future price: according to them, MLLCF price has a max estimate of 21.28 USD and a min estimate of 4.38 USD. Watch MLLCF chart and read a more detailed Molecular Partners AG stock forecast: see what analysts think of Molecular Partners AG and suggest that you do with its stocks.
MLLCF reached its all-time high on Feb 12, 2021 with the price of 33.00 USD, and its all-time low was 3.40 USD and was reached on Oct 31, 2023. View more price dynamics on MLLCF chart.
See other stocks reaching their highest and lowest prices.
MLLCF stock is 1.43% volatile and has beta coefficient of 0.89. Track Molecular Partners AG stock price on the chart and check out the list of the most volatile stocks — is Molecular Partners AG there?
Today Molecular Partners AG has the market capitalization of ‪139.86 M‬, it has increased by 1.59% over the last week.
Yes, you can track Molecular Partners AG financials in yearly and quarterly reports right on TradingView.
Molecular Partners AG is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
MLLCF earnings for the last quarter are −0.69 USD per share, whereas the estimation was −0.49 USD resulting in a −41.03% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Molecular Partners AG earnings.
Molecular Partners AG revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MLLCF net income for the last quarter is ‪−25.71 M‬ USD, while the quarter before that showed ‪−18.95 M‬ USD of net income which accounts for −35.71% change. Track more Molecular Partners AG financial stats to get the full picture.
No, MLLCF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 9, 2025, the company has 174 employees. See our rating of the largest employees — is Molecular Partners AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Molecular Partners AG EBITDA is ‪−73.05 M‬ USD, and current EBITDA margin is ‪−1.18 K‬%. See more stats in Molecular Partners AG financial statements.
Like other stocks, MLLCF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Molecular Partners AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Molecular Partners AG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Molecular Partners AG stock shows the sell signal. See more of Molecular Partners AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.